Read the full stored bill text
A bill for an act
relating to health; establishing the Minnesota Community Pharmacy Patient Access
and Fair Reimbursement Act; requiring rulemaking; proposing coding for new
law in Minnesota Statutes, chapter 62J.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
Section 1.
new text begin
[62J.901] MINNESOTA COMMUNITY PHARMACY PATIENT ACCESS
AND FAIR REIMBURSEMENT ACT.
new text end
new text begin
Subdivision 1.
new text end
new text begin
Title.
new text end
new text begin
This section shall be known as the "Minnesota Community
Pharmacy Patient Access and Fair Reimbursement Act."
new text end
new text begin
Subd. 2.
new text end
new text begin
Scope.
new text end
new text begin
This section is intended to protect patients' access to community
pharmacies by ensuring sustainable reimbursement rates for community pharmacies and to
prevent unfair reimbursement practices that cause pharmacy closures, thereby safeguarding
patient access to essential pharmaceutical care and maintaining a strong community health
infrastructure across the state. This section regulates pharmacy benefit manager conduct
and reimbursement practices and does not alter health plan benefit design or federal program
requirements.
new text end
new text begin
Subd. 3.
new text end
new text begin
Definitions.
new text end
new text begin
(a) For purposes of this section, the following terms have the
meanings given.
new text end
new text begin
(b) "Community pharmacy" means an outpatient retail pharmacy licensed under chapter
151 that is not owned, operated, managed, or controlled, either directly or indirectly, through
an affiliate or subsidiary by a:
new text end
new text begin
(1) pharmacy benefit manager licensed under chapter 62W;
new text end
new text begin
(2) health carrier, as defined in section 62A.011, subdivision 2;
new text end
new text begin
(3) government entity;
new text end
new text begin
(4) mail-order pharmacy; or
new text end
new text begin
(5) specialty pharmacy.
new text end
new text begin
(c) "National Average Drug Acquisition Cost" or "NADAC" means the publicly available,
federally established benchmark reflecting the average acquisition cost of outpatient
prescription drugs purchased by retail community pharmacies, as determined by the Centers
for Medicare and Medicaid Services.
new text end
new text begin
(d) "Pharmacy benefit manager" or "PBM" has the meaning given in section 62W.02,
subdivision 15.
new text end
new text begin
(e) "Pharmacy reimbursement ceiling" means the maximum reimbursement rate for
prescription drugs dispensed by a pharmacy established under subdivision 4.
new text end
new text begin
(f) "Professional dispensing fee" means the fee paid to a pharmacy for the cost of
dispensing a medication, excluding the cost of the drug itself. The fee is intended to cover
the professional services provided by the pharmacy dispensing the medication, in accordance
with section 256B.0625, subdivision 13e.
new text end
new text begin
(g) "Wholesale acquisition cost" or "WAC" means the manufacturer's list price for a
prescription drug to wholesalers or direct purchasers in the United States, not including any
discounts, rebates, or other price concessions.
new text end
new text begin
Subd. 4.
new text end
new text begin
Fair pharmacy reimbursement.
new text end
new text begin
(a) Except as provided in paragraph (c), this
subdivision applies to prescription drugs dispensed by a community pharmacy, as defined
in subdivision 3, and to claims adjudicated by a PBM under a health plan or pharmacy
benefit plan.
new text end
new text begin
(b) To improve patient access to pharmacy services and support the financial viability
of community pharmacies, for any prescription drug dispensed by a community pharmacy
and for any claim adjudicated by a PBM to which this subdivision applies, the total
reimbursement to the community pharmacy must be equal to:
new text end
new text begin
(1) the NADAC for the drug on the day of claim adjudication or, if the NADAC is
unavailable, the WAC for that drug on the day of claim adjudication, plus an additional
amount equal to four percent of the calculated total ingredient cost as derived from the
applicable NADAC or WAC amount, or $50, whichever is less; and
new text end
new text begin
(2) a professional dispensing fee as specified in section 256B.0625, subdivision 13e,
which must be equal to the professional dispensing fee paid by the state under the medical
assistance program and adjusted biennially based on an independent cost-of-dispensing
survey reflecting inflation, labor costs, and operational expenses.
new text end
new text begin
(c) The reimbursement standard established in this subdivision constitutes both the
minimum and maximum reimbursement amount for purposes of this section and may not
be altered by contract, network design, or other reimbursement methodology.
new text end
new text begin
Subd. 5.
new text end
new text begin
Scope of application; covered entities; exclusions.
new text end
new text begin
(a) Nothing in this section
requires reimbursement at or above NADAC or WAC for drugs purchased under the federal
340B Drug Pricing Program. Reimbursement for drugs purchased under the 340B program
must comply with applicable state and federal law.
new text end
new text begin
(b) This section does not apply to claims paid under Medicare or Medicaid, including
claims paid under Medicare Part B, Medicare Part D, and Medicaid fee-for-service or
managed care, or under any other state or federal program for which reimbursement is
established by statute, regulation, state plan, contract approved by a federal agency, or
federal waiver.
new text end
new text begin
(c) This section regulates the reimbursement practices of pharmacy benefit managers
licensed under chapter 62W with respect to claims paid under commercial health plans and
pharmacy benefit plans subject to state regulation.
new text end
new text begin
Subd. 6.
new text end
new text begin
Prohibition on below-cost and postclaim manipulation.
new text end
new text begin
(a) A PBM must
not reimburse a community pharmacy in an amount below the reimbursement standard
established in this section.
new text end
new text begin
(b) A PBM must not impose any fee, adjustment, recoupment, reconciliation payment,
performance metric, direct or indirect remuneration fee, or other mechanism that results in
a community pharmacy receiving less than the total reimbursement required under this
section.
new text end
new text begin
Subd. 7.
new text end
new text begin
Ban on spread pricing.
new text end
new text begin
PBMs are prohibited from engaging in spread pricing
in commercial and state-regulated plans. A PBM may not retain any portion of payments
made by a health plan, insurer, government program, or other payer beyond the amount
paid to the dispensing pharmacy, less enrollee cost sharing. PBMs must remit to the
dispensing pharmacy 100 percent of payments received, less patient cost-sharing.
new text end
new text begin
Subd. 8.
new text end
new text begin
Prohibition of retroactive claim denials.
new text end
new text begin
PBMs must not retroactively deny
or reduce claim reimbursement except in cases of fraud, billing errors, or documented
overpayment verified through an audit.
new text end
new text begin
Subd. 9.
new text end
new text begin
Prohibition on patient steering.
new text end
new text begin
PBMs must not require, coerce, steer, or
financially penalize an enrollee to use a PBM-owned, affiliated, or mail-order pharmacy.
A PBM must not impose higher cost-sharing, reduced benefits, or other financial or
administrative disadvantages on an enrollee who chooses to obtain prescription drugs from
a community pharmacy.
new text end
new text begin
Subd. 10.
new text end
new text begin
Enforcement and penalties.
new text end
new text begin
(a) The Department of Commerce has exclusive
authority to administer and enforce this section.
new text end
new text begin
(b) A community pharmacy, health carrier, plan sponsor, or enrollee may file a complaint
with the commissioner alleging a violation of this section. The commissioner shall investigate
alleged violations and may require the submission of claims data, pricing files, contracts,
and any other records necessary to determine compliance.
new text end
new text begin
(c) To ensure compliance with this section, the commissioner may:
new text end
new text begin
(1) conduct investigations and compel the production of unredacted records, pricing
agreements, claims data, contracts, and internal communications relevant to reimbursement
practices;
new text end
new text begin
(2) order corrective action including restitution, cease-and-desist orders, and prospective
pricing adjustments to remedy and prevent violations;
new text end
new text begin
(3) require annual compliance certification from PBMs attesting to full compliance with
this section. A false certification is subject to civil penalties and potential suspension of
licensure; and
new text end
new text begin
(4) publish an annual compliance report summarizing:
new text end
new text begin
(i) the number of violations identified;
new text end
new text begin
(ii) the amount of fines and restitution collected; and
new text end
new text begin
(iii) the impact on community pharmacy access and closures.
new text end
new text begin
(d) A PBM found to be reimbursing below the reimbursement standard established in
subdivision 4 is subject to a civil penalty of $5,000 per violation per claim. Repeat violations
are subject to escalating penalties of up to $20,000 per claim, not to exceed $2,000,000 per
enforcement action. The Department of Commerce may impose additional sanctions,
including suspension or revocation of a PBM's license to operate in the state.
new text end
new text begin
(e) If the commissioner determines that a PBM has violated this section, the commissioner
may:
new text end
new text begin
(1) order full restitution to the affected pharmacy, including interest and reasonable costs
incurred in the administrative proceeding; and
new text end
new text begin
(2) impose any additional sanctions authorized under this section.
new text end
new text begin
(f) A pharmacist or other individual who, in good faith, reports noncompliance, fraudulent
reimbursement practices, or retaliatory conduct by a PBM is protected from retaliation. The
commissioner shall establish a secure and confidential process for receiving reports. Verified
violations may result in additional penalties or corrective action.
new text end
new text begin
(g) A final order of the commissioner is subject to judicial review under chapter 14.
new text end
new text begin
Subd. 11.
new text end
new text begin
Rulemaking.
new text end
new text begin
The commissioner of commerce shall adopt necessary rules to
implement this section.
new text end
new text begin
Subd. 12.
new text end
new text begin
Severability.
new text end
new text begin
If any provision of this section or its application to any person
or circumstance is held invalid, the invalidity does not affect other provisions or applications
of the section that can be given effect without the invalid provision or application.
new text end
new text begin
EFFECTIVE DATE.
new text end
new text begin
This section is effective July 1, 2026.
new text end